Provexis Regulatory News (PXS)

17 June 2011 Provexis plc

("Provexis" or the "Company")

PRELIMINARY RESULTS for the YEAR ended 31 MARCH 2011

Provexis plc (PXS.L), the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces its audited preliminary results for the year ended 31 March 2011.

Key highlights

·; The Company has entered into a conditional agreement to acquire SiS (Science in Sport) Limited for a consideration of £8m, partially funded by a £2.5m conditional placing at 1.5 pence per share, which is expected to complete on 24 June 2011.

·; Good progress to commercialise Fruitflow® heart-health technology in all major global markets under the Alliance Agreement with DSM Nutritional Products.

·; Clinical trial for NSP#3G for Crohn's disease patients progressed through interim review with focus now on opening new trial centres to complete patient recruitment.

·; Collaboration with Institute of Food Research for the reduction of cardiovascular inflammation and the reduction of risk of certain cancers making good progress with the first human trials underway.

·; Agreement entered into with DSM Nutritional Products to develop technology for management of blood glucose.

·; £2.5m total funding raised through Equity Financing Facility in June 2010 and October 2010.

Key financial results

·; Loss attributable to owners of the parent £2.0m (2010: £1.6m).

·; Cash balance £7.6m (2010: £7.0m).

·; Loss per share 0.17p (2010: 0.18p).

Stephen Moon, Chief Executive Officer of Provexis plc, commented:

"We are delighted to announce that the Company has entered into a conditional agreement to acquire SiS (Science in Sport) Limited which is expected to complete on 24 June 2011. Science in Sport is a highly regarded and growing company in the substantial sector of sports nutrition. I believe there are strong synergies between the two businesses, with the existing scientific, regulatory and product development capability of Provexis available to further enhance the reputation of Science in Sport with elite and professional athletes. The revenue generating, profitable nature of the new business will help us to achieve our strategic goals, by adding a near term revenue stream to our longer-term pipeline development bias. Management of the enlarged business will be highly focused on growing revenues from our Fruitflow® heart-health Alliance with DSM Nutritional Products, the new Science in Sport business and continuing to build longer-term shareholder value from our pipeline."

-ends-

Enquiries:

Chairman's statement

The business has made substantial progress this year through the development of its long-term, global commercial agreement with DSM for our lead Fruitflow® technology, in addition to the broader pipeline being extended and developed.

I can announce that we are about to meet our objective of making an acquisition, as we today announce that the Company has entered into a conditional agreement to purchase SiS (Science in Sport) Limited, which is expected to complete on 24 June 2011. The business develops, manufactures and sells nutrition products for sports people and its heritage is in providing nutrition products for professional and elite athletes. In addition to bringing revenues and cash flow to the Company, there is a great synergy between the two businesses and we believe our existing scientific and regulatory skills will help the acquired business to cement further its reputation in its target sectors.

Following the signing of our Alliance Agreement with DSM on 1 June 2010, good progress has been made in the commercialisation of our lead heart-health Fruitflow® technology. DSM launched Fruitflow® to the industry in Europe in November 2010 and in the US in March 2011. DSM has made significant progress in marketing the technology in a broad range of global markets, attracting positive interest from a wide range of global, multinational and national brand owners in the functional food and dietary supplement sectors. We are pleased with the progress made by DSM.

Having a broader pipeline remains central to our strategy and progress has been made on a number of fronts. While we have been frustrated with the slow progress in patient recruitment for our NSP#3G Crohn's disease trial, an independent interim review of trial data has given us confidence to open further patient centres. Our collaboration with the Institute of Food Research, with an initial objective of developing a product for cardiovascular inflammation, is proceeding well and a first human trial is underway. We recently entered into a development agreement with DSM where the Company will bring its scientific and regulatory expertise to bear to commercialise DSM owned intellectual property.

With our first commercial deal for Fruitflow®, a major acquisition and the expansion of our pipeline, it has been a busy year and I would like to thank the executive team, all of our staff and our advisors for their efforts and professionalism.

Dawson Buck

Chairman

Chief Executive's statement

Strategy

We have continued to execute our strategy of discovery, development and licensing functional food, medical food and dietary supplements. Our intention to make acquisitions in order to develop shareholder value has been realised through our entering into a conditional agreement to acquire SiS (Science in Sport) Limited ("SiS"), which is expected to complete on 24 June 2011. We believe that there is good synergy between the two businesses and that our existing scientific and regulatory expertise can assist in making the SiS business a leader in claims-supported sports nutrition.

The Provexis business model now extends from discovery, through development and now to market by a combination of licensing and direct sales revenues. The Directors believe that this gives the business the correct balance of short-term revenues and long-term pipeline potential.

The executive team will continue to seek further acquisitions as part of the long-term aim to strengthen the pipeline. We have continued to invest in top quality management expertise in order to assist the Company in meeting its strategic goals and this policy will continue.

To support our strategy, we raised £2.5m via our Equity Financing Facility in June and October 2010, with a further £2.5m from the conditional placing announced today. Together, these fund raising events will enable us to undertake the acquisition of SiS, which is expected to complete on 24 June 2011, and deliver on our strategic plan in 2010/2011.

Fruitflow®

The Company announced on 1 June 2010 that it had entered into a long-term alliance with DSM Nutritional Products ("DSM") to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications (the "Alliance").

DSM launched Fruitflow® to the industry in Europe in November 2010 and in the US in March 2011. Manufacturing and supply chain for a cost effective syrup version of Fruitflow® has been secured. Also good progress has been made on optimising the powder version of Fruitflow®, suitable for formats such as tablets and capsules, and this format will be commercially available late in the summer.

Fruitflow® has been recognised in the industry for its strong science and innovation, being awarded the 'Most Innovative Health Ingredient' and winning the best innovation in the 'Heart Health' category at the major Health Ingredients Europe Conference in November 2010. In March 2011 the technology was awarded 'Best New Ingredient' at the 2011 NutrAwards held at the Nutracon 2011 exhibition in Anaheim, California.

The Alliance partners continue to collaborate on regulatory matters related to certain markets. In addition, the Provexis scientific team continues to support its counterparts in areas such as analytical methods and analysis, together with deepening the understanding of the core science.

DSM has made significant progress in marketing the technology in a broad range of global markets, attracting positive interest from a wide range of global, multinational and national brand owners in the functional food and dietary supplement sectors. The Directors are pleased with the progress being made in the marketplace by the Company's Alliance partner.

NSP#3G plantain extract

A fully independent Data Monitoring Committee ("DMC") has reviewed the data gathered from the first patients to complete the full 12 months of treatment in the Crohn's disease trial. Following their review, the DMC has confirmed that there are no negative findings associated with this initial dataset and no safety concerns related to the administration of the test product. The DMC recommended a further interim review of the study be conducted in Q4 2011. The interim review findings are in line with the Company's expectations.

Following this advice, Provexis intends to identify up to four additional trial centres to facilitate full recruitment of the remaining patients required, to enable it to complete the trial in the shortest feasible timeline. The Directors have previously noted that the recruitment of patients for clinical trials in the area of inflammatory bowel disease is recognised as being challenging across the industry. The Company remains committed to this key technology and believes that opening extra trial centres will expedite the trial and support initial commercial discussions with corporate partners.

The Company's Liverpool-based R&D team will also continue to research and characterise NSP#3G extracts for addressing C.difficile, the so-called hospital 'super bug', and antibiotic-associated diarrhoea.

Isothiocyanates

The isothiocyanate-based cardiovascular inflammation work in collaboration with Institute of Food Research ("IFR") is proceeding well. A novel extract has been developed and the first human trial has now commenced. A second trial will commence later this year, with a third and final trial to provide regulatory support for product launches being scheduled for 2012.

Blood glucose

We recently announced an agreement for development of DSM-owned intellectual property for the promotion of healthy blood glucose levels, following a period of assessment by Provexis. Under the agreement, it is the intention that Provexis will develop a cost effective product, carry out clinical trials and gain the necessary regulatory clearances. DSM will contribute intellectual property and know-how to the development programme. The partners will together identify the most appropriate commercialisation arrangements before the product is launched.

Outlook

The commercial progress of Fruitflow® is an important objective for the Company in the coming financial period and we expect to see progress as our Alliance partner DSM continues its marketing and selling efforts, in addition to launching the powder version for dietary supplements.

Integrating the SiS business is the second major objective and we look to complete this as quickly as possible in order to focus existing and new management members on growing revenues in this business.

It is important that we reach full recruitment in the Crohn's disease trial during this year, in order that commercial partnering discussions can commence. The isothiocyanate technology platform and the new blood glucose technology will both be accelerated in order we can bring these to market in the earliest possible time.

The management team will be focused on progress in the revenue generating areas of Fruitflow® and SiS, while not losing sight of the medium and long term importance of the broader pipeline. Cash management will continue to be an area of high importance. We will maintain our strategy of developing the capability of the overall Provexis team in line with our goals.

Stephen Moon

Chief Executive

Financial Review

International Financial Reporting Standards

The Financial Review should be read in conjunction with the Group financial information including the notes to the Group financial information.

Revenue and grant income

Revenue for the year ended 31 March 2011 was £50,086 (2010: £14,767).

Grant income for the year ended 31 March 2011 was £ Nil (2010: £80,000), the amount in 2010 being the final part of a £100,000 grant which was awarded to the Group in January 2009 by The Northwest Regional Development Agency (NWDA).

Research and development costs

Research and development ("R&D") costs for the year ended 31 March 2011 were £1,268,874 (2010: £718,468), including £17,959 capitalised under IAS 38 (2010: £20,646), reflecting the recruitment of additional R&D staff, continuation of the clinical trial for the Group's NSP#3G technology for Crohn's disease and the commencement of isothiocyanate-based cardiovascular inflammation work in collaboration with the Institute of Food Research ("IFR").

R&D expenditure comprises in-house costs (staff, R&D consumables, intellectual property, facilities and depreciation of R&D assets) and external costs (preclinical studies, manufacturing, regulatory affairs and clinical trials).

The Group's R&D team continues to research further claim areas for the Group's technologies.

The Group aims to achieve cost effective research and development and to bring products to market through licensing partners as soon as is practicable.

Administrative costs

Administrative costs for the year relating to continuing operations were £1,274,493 (2010: £1,184,859).

The Group's cost base and its resources have been and will continue to be tightly managed.

Taxation

A research and development tax credit of £221,218 (2010: £54,408) of which £71,228 related to the prior year in respect of research and development expenditure incurred has been recognised in the financial information and is shown as a debtor at 31 March 2011.

Losses and dividends

The loss attributable to owners of the parent for the year ended 31 March 2011 was £1,986,206 (2010: £1,648,180) and the loss per share was 0.17p (2010: 0.18p).

The directors do not recommend the payment of a dividend (2010: £ Nil).

Effect of change in accounting standard

The application of the following standard has resulted in the losses attributable to the non-controlling interest being accounted for in the financial information even where this resulted in the non-controlling interest having a deficit balance:

• IAS 27 (Amendment) 'Consolidated and Separate Financial Statements' effective for periods beginning on or after 1 July 2009.

For further Information about this change in accounting standard see the Principal risks and uncertainties section of the business overview.

Financial instruments

Information about the use of financial instruments by the Group is disclosed in notes 1 and 2.

Capital structure and funding

The group is funded entirely by equity funding.

On 31 March 2010 the Company announced that it had secured a 3 year Equity Financing Facility of up to £25m (the "EFF") with Evolution Securities Limited ("Evolution"). The EFF has been arranged by Darwin Strategic Limited ("Darwin"), an appointed representative of Evolution.

On 22 June 2010 the Company announced that it had raised a net £88,426 by drawing down on the EFF, allotting 2,135,000 new ordinary shares of 0.1p each to Darwin.

On 4 October 2010 the Company announced that it had raised a further net £2.4m by drawing down on the EFF, allotting 86,300,000 new ordinary shares of 0.1p each to Darwin.

The Directors are of the opinion that at 17 June 2011, the Group's liquidity and capital resources are adequate to deliver the current strategic objectives and 2011/12 business plan and that the Group meets going concern criteria. See also note 1.

Cash at bank at 31 March 2011 was £7,551,505 (31 March 2010: £7,049,134).

Post balance sheet events

As disclosed in note 23, on 1 June 2011 the Group announced an agreement to commercialise DSM owned intellectual property, through the development of a new product for the promotion of healthy blood glucose levels.

On 17 June 2011 the Group entered into a conditional agreement to acquire 100% of the issued share capital of SiS, a company which manufactures and sells sports nutrition products for a maximum consideration of £8m, subject to completion. £7m is payable in cash of which £250,000 is to be held in escrow against claims for one year or longer if claims have been notified but not settled. The balance of the consideration is £1m in Provexis shares, with a lock-in of two years. 

The £7m cash consideration will be met by £4.5m from current cash reserves and £2.5m from a placing for new shares. The Company intends to undertake an Open Offer to shareholders of the Company as soon as is reasonably practicable after the completion of the Acquisition.

Principal risks and uncertainties

The Directors consider that the key risks of the Group are as set out below:

The Group's success will depend in part on its ability to obtain and maintain rigorous patent protection for its technologies both in the UK and internationally. The Group cannot give definitive assurance that pending or future patent applications will be granted or that patents granted will not be challenged, invalidated or held unenforceable.

The Group cannot assure that its intellectual property rights are sufficiently broad to prevent third parties from producing competing functional food, medical food and dietary supplement technologies similar in nature to its own. The Group also relies on protection of trade secrets, know-how and confidential and proprietary information. To mitigate this, the Group enters into non-disclosure agreements with employees, consultants and prospective commercial partners but cannot assure that such agreements will provide complete safeguards against unauthorised disclosure of confidential information.

The Group's commercial success will also depend in part on avoiding infringement of other third parties' patents or proprietary rights and the breach of any licences in connection with the pursuit of its technologies. Management is of the opinion that it does not infringe third parties' patents or other rights and is not aware of any such infringements but cannot assure that it will not be found in the future to infringe such rights.

The Group has a limited pipeline of new technologies and new indications for technologies already in development. As a result of regulatory and competitive uncertainties and the unpredictability of successful outcomes to new research and development, the Group cannot provide assurance that it will be able to develop and license these new technologies.

The Group continues to pursue acquisitions as part of its growth strategy. Such acquisitions may not realise

expected benefits.

Principal risks and uncertainties (continued)

The Group may require additional funding. To the extent that the current cash resources of the Group and the funds received from the Open Offer are insufficient to cover the Group's liabilities in the longer term it may be necessary to seek additional funds through future equity or debt financings and there is no certainty that such funds would be available. Any such further financings, if available at all, may be on terms that are not favourable to the Group. Further, if adequate capital cannot be obtained, the Group's operating results and financial condition could be adversely affected.

The Group currently employs fourteen people, excluding Non-executive Directors, and has a very small management team. Should it lose any key management resources and be unable to attract replacements of equivalent calibre to continue implementation of its business plan, future development and commercial activities could be materially adversely affected.

The Group relies on potential license partners to meet certain commercial and development milestones and their failure to achieve this, or other delays or cancellation of projects due to internal or market factors affecting potential license partners could affect the execution of the Group's business plan, with a material adverse effect on the business. In these circumstances the Group would look to raise additional funding through the issue of additional equity through rights issues, share placing and the exercise of share options but no assurance can be given regarding the successful outcome of such financing initiatives.

As noted previously the Group is not able to predict successful outcomes to research and development. The non-controlling interest share of Provexis (IBD) Limited's loss would need to be reversed if the project didn't come to fruition. At 31 March 2011 this would increase the loss attributable to the equity holders of the parent by £136,459 to £2,120,665.

Ian Ford

Finance Director

Consolidated statement of comprehensive income

Consolidated statement of financial position

Consolidated statement of cash flows

Consolidated statement of changes in equity

The total comprehensive expense for the year represents the total recognised income and expense for the year.

Notes to the preliminary results for the year ended 31 March 2011

1. Accounting policies

General information

Provexis plc is a public limited company incorporated and domiciled in the United Kingdom (registration number 05102907). The address of the registered office is Thames Court, 1 Victoria Street, Windsor, Berkshire SL4 1YB, UK.

The main activities of the Group are those of discovering, developing and licensing scientifically-proven technologies for the global functional food, medical food and dietary supplement sectors.

Basis of preparation

This preliminary announcement does not constitute the Company's statutory accounts for the year ended 31 March 2011 for the purposes of section 435 of the Companies Act 2006, but it is derived from those accounts. Statutory accounts for 2010 have been delivered to the Registrar of Companies. Statutory accounts for 2011 will be delivered following the Company's Annual General Meeting. The auditors have reported on both the 2010 and 2011 accounts: their reports were unqualified, did not draw attention to any matters by way of emphasis and did not contain any statement under section 498 (2) or (3) of the Companies Act 2006.

While the financial information included in this preliminary announcement has been prepared in accordance with the recognition and measurement criteria of International Financial Reporting Standards (IFRS), this announcement does not itself contain sufficient information to comply with IFRS. The Company expects to publish full financial statements for the year ended 31 March 2011 that comply with IFRS in June 2011.

The accounting policies set out below have been applied to all periods presented in these Group financial results and are in accordance with IFRS, as adopted by the European Union, and International Financial Reporting Interpretations Committee ("IFRIC") interpretations that were applicable for the year ended 31 March 2011.

The following new standards, amendments to standards and interpretations, applied for the first time from 1 April 2010:

• IFRS 3 (Revised) 'Business Combinations' effective for periods beginning on or after 1 July 2009;

• Improvements to IFRSs (2009) effective for periods beginning on or after 1 January 2010; and

• IFRS 2 (Amendment) 'Share-based Payment: Group Cash-settled Share-based Payment Transactions' effective for periods beginning on or after 1 January 2010.

The adoption of these standards and interpretations has not had any significant impact on the amounts reported in these financial results but may impact the accounting for future transactions and arrangements.

The application of the following standard has resulted in the losses attributable to the non-controlling interest being accounted for in the financial results even where this resulted in the non-controlling interest having a deficit balance:

• IAS 27 (Amendment) 'Consolidated and Separate Financial Statements' effective for periods beginning on or after 1 July 2009.

The Directors have determined that only one operating segment exists under the terms of International Financial Reporting Standard 8 'Operating Segments', as the Group is organised and operates as a single business unit and all activities are based in the UK..

The following new standards, amendments to standards and interpretations have been issued but are not effective for the year ended 31 March 2011. The new standards, amendments to standards and interpretations will be relevant to the Group but have not been adopted early as the Directors do not expect these standards and interpretations to have a material effect on the consolidated financial results:

·; IFRS 9 'Financial Instruments' is effective from periods commencing on or after 1 January 2013.

·; IAS 24 (Amended) 'Related party disclosures' is effective from periods commencing on or after 1 January 2011.

There are a number of standards, interpretations and amendments to published accounts not listed above which the Directors consider not to be relevant to the Group.

1. Accounting policies (continued)

Going concern

The financial position of the Group, its cash flows and liquidity position together with the factors likely to affect its future development are set out in the Financial Review. In addition note 2 to the financial results includes the Group's objectives, policies and processes for managing its capital; its financial risk management objectives; details of its financial instruments and its exposure to credit and liquidity risk.

The Group made a loss for the year attributable to owners of the parent of £1,984,206 (2010: £1,648,180) and expects to make a further loss during the year ending 31 March 2012. At 31 March 2011 the Group had cash balances of £7,551,505 (2010: £7,049,134).

The directors have prepared projected cash flow information for a period including twelve months from the date of approval of these financial results and have reviewed this information as at the date of these financial results. Based on the level of existing cash, projected income and expenditure and other sources of funding, the Directors are satisfied that the Company and the Group have adequate resources to continue in business for the foreseeable future. Accordingly the going concern basis has been used in preparing the financial results.

Basis of consolidation

Subsidiaries are all entities (including special purpose entities) over which the Group has the power to govern the financial and operating policies generally accompanying a shareholding of more than one half of the voting rights. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

The consolidated financial information presents the results of the Company and its subsidiaries, Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited as if they formed a single entity ("the Group"). All subsidiaries share the same reporting date, 31 March, as Provexis plc. All intra group balances are eliminated in preparing the financial results.

The purchase method of accounting is used to account for the acquisition of subsidiaries by the Group. The cost of an acquisition is measured as the fair value of the assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any non-controlling interest. The excess of the cost of acquisition over the fair value of the Group's share of the identifiable net assets acquired is recorded as goodwill.

Non-controlling interest

Profit or loss and each component of other comprehensive income are attributed to the owners of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Revenue

Revenue comprises the fair value received or receivable for exclusivity arrangements, collaboration agreements, royalties and sales of the Group's Fruitflow® product net of value added tax.

The accounting policies for the principal revenue streams of the Group are as follows:

(i) Exclusivity arrangements and similar agreements are recognised as revenue in the accounting period in which the related services, or required activities, are performed or specified conditions are fulfilled in accordance with the terms of completion of the specific transaction.

(ii) Royalty income relating to the sale by a licensee of licensed product is recognised on an accruals basis in accordance with the substance of the relevant agreement and based on the receipt from the licensee of the

relevant information to enable calculation of the royalty due.

(iii) Sales of the Group's Fruitflow® product are recorded net of value added tax when the significant risks and rewards of ownership have been transferred to the buyer.

1. Accounting policies (continued)

Leased assets

Leases, which contain terms whereby the Group does not assume substantially all the risks and rewards incidental to ownership of the leased item are classified as operating leases. Operating lease rentals are charged to the statement of comprehensive income on a straight line basis over the lease term. The Group does not hold any assets under finance leases.

Intangible assets

Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of the Group's share of the identifiable net assets acquired. Goodwill on acquisition of subsidiaries is included in 'intangible assets'. Separately recognised goodwill is tested annually for impairment and carried at cost less accumulated impairment losses.

An impairment loss is recognised within administrative expenses in the consolidated statement of comprehensive income for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.

Impairment losses on goodwill are not reversed.

Research and development

Certain Group products are in the research phase and others are in the development phase. Expenditure incurred on the development of internally generated products is capitalised if it can be demonstrated that:

● It is technically feasible to develop the product for it to be sold;

● Adequate resources are available to complete the development;

● There is an intention to complete and sell the product;

● The Group is able to sell the product;

● Sale of the product will generate future economic benefits; and

● Expenditure on the project can be measured reliably.

The value of the capitalised development cost is assessed for impairment annually. The value is written down immediately if impairment has occurred. Development costs are not being amortised as income has not yet been realised from the underlying technology.

Development expenditure, not satisfying the above criteria, and expenditure on the research phase of internal projects is recognised in the statement of comprehensive income as incurred.

Patents and trademarks

The costs incurred in establishing patents and trademarks are either expensed or capitalised in accordance with the corresponding treatment of the development expenditure for the product to which they relate.

Plant and equipment

Plant and machinery, fixtures, fittings and computer equipment and laboratory equipment are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Depreciation is charged to the statement of comprehensive income on all plant and equipment at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight line basis over their estimated useful lives, which is 3 years for plant and machinery, fixtures, fittings and computer equipment and 5 years for laboratory equipment.

The assets' residual values and useful lives are determined by the Directors and reviewed and adjusted if appropriate at each balance sheet date in accordance with the Group policy for impairment of assets.

1. Accounting policies (continued)

Impairment of assets

Assets that have a finite useful life but that are not yet in use and are therefore not subject to amortisation or depreciation are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment annually and when events or circumstances suggest that the carrying amount may not be recoverable, an impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Goodwill is allocated to cash-generating units ('CGU') for the purpose of impairment testing to the extent that it is possible to allocate goodwill to a CGU on a non-arbitrary basis. A CGU is identified at the lowest aggregation of assets that generate largely independent cash inflows, and that which is looked at by management for monitoring and managing the business.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in the statement of comprehensive income, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior periods. A reversal of an impairment loss is recognised immediately in the statement of comprehensive income, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Financial instruments

Financial assets

The Group's financial assets are comprised of 'trade and other receivables' and 'cash and cash equivalents'. They are recognised initially at their fair value and subsequently at amortised cost. The Group will assess at each balance sheet date whether there is objective evidence that the financial asset is impaired. If an asset is judged to be impaired the carrying amount of the asset will be adjusted to its impaired valuation.

Financial liabilities

The Group's financial liabilities comprise 'trade and other payables'. These are recognised initially at fair value and subsequently at amortised cost.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand.

Government grants

Government grants are recognised when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions. Government grants are recognised in the statement of comprehensive income in the same period to which the costs that they are intended to compensate are expensed.

Taxation

Current tax is provided at amounts expected to be recovered or to be paid using the tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. When research and development tax credits are claimed they are recognised on an accruals basis and are included as a taxation credit.

Deferred tax assets and liabilities are recognised where the carrying amount of an asset or liability on the balance sheet differs from its tax base, except for differences arising on:

·; The initial recognition of goodwill

·; The initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting or taxable profit; and

·; Investments in subsidiaries where the Group is able to control the timing of the reversal of the difference and it is probable that the difference will not reverse in the foreseeable future.

1. Accounting policies (continued)

Taxation (continued)

Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profits will be available against which the difference can be utilised.

The amount of the asset or liability is determined using tax rates that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the deferred tax liabilities/(assets) are settled/(recovered). Deferred tax balances are not discounted.

Deferred tax assets and liabilities are offset when the Group has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority on either:

·; The same taxable Group Company; or

·; Different Group entities which intend to settle current tax assets and liabilities on a net basis, or to realise the assets and settle the liabilities simultaneously, on each future period in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.

Foreign currency translation

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the statement of comprehensive income.

Employee benefits

(i) Defined contribution plans

The Group provides retirement benefits to all employees and Executive Directors. The assets of these schemes are held separately from those of the Group in independently administered funds. Contributions made by the Group are charged to the statement of comprehensive income in the period in which they become payable.

(ii) Accrued holiday pay

Provision has been made at the balance sheet date for holidays accrued but not taken at the salary of the relevant employee at that date.

(iii) Share-based payment transactions

The Group operates an equity-settled, share-based compensation plan. Vesting conditions are service conditions and performance conditions only. Where share options are awarded to employees and others providing similar services, the fair value of the options at the date of grant is charged to the statement of comprehensive income over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options when granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions are satisfied. The cumulative charge is not adjusted for failure to achieve a market vesting condition. If market related terms and conditions of options are modified before they vest, the change in the fair value of the options, measured immediately before and after the modification, is also charged to the statement of comprehensive income over the remaining vesting period. If non-market related terms and conditions of options are modified before they vest, the number of instruments expected to vest at each balance sheet date, and therefore the cumulative charge, is therefore amended accordingly. Where equity instruments are granted to persons other than employees and others providing similar services, the statement of comprehensive income is charged with the fair value of goods and services received.

The proceeds received when options are exercised, net of any directly attributable transaction costs, are credited to share capital (nominal value) and the remaining balance to share premium.

National insurance on share options

All employee option holders sign statements that they will be liable for any employers national insurance arising on the exercise of share options.

1. Accounting policies (continued)

Interest income

Interest income is recognised on a time-proportion basis using the effective interest rate method.

Warrants

The Group has issued warrants to Evolution Securities Limited as part of the Equity Financing Facility. These are considered to be outside the scope of share-based employee remuneration, and hence out of the scope of IFRS 2. These warrants have been measured at fair value at the date of grant using an appropriate options pricing model. This fair value has been held on the balance sheet within prepayments and in the warrants reserve within equity. The prepayment will be released against share premium as the equity financing facility is utilised. The warrants reserve will be released to share premium when the warrants are exercised. If the warrants lapse then the reserve is transferred to retained earnings.

Critical accounting estimates and judgements

The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and judgements are continually made and are based on historic experience and other factors, including expectations of future events that are believed to be reasonable in the circumstances.

As the use of estimates is inherent in financial reporting, actual results could differ from these estimates. The Directors believe the following to be the key areas of estimation and judgement:

(i) Research and development

Under IAS 38 Intangible Assets, development expenditure which meets the recognition criteria of the standard must be capitalised and amortised over the useful economic lives of intangible assets from product launch. The Directors consider that the criteria to capitalise development expenditure were met in 2007 for one of the Group's products and have continued to be met since.

(ii) Share-based payments

The Group operates an equity-settled, share-based compensation plan. Employee and similar services received, and the corresponding increase in equity, are measured by reference to the fair value of the equity instruments at the date of grant, which is based upon certain assumptions over the future performance of the share price.

(iii) Goodwill and impairment

The recoverable amount of goodwill is determined based on value in use calculations of the cash-generating units to which it relates. The value in use calculations use pre-tax cash flow projections for nine years using data from the Group's latest internal forecasts. The revenue forecasts are extrapolated beyond nine years and costs are extrapolated beyond two years at growth rates of 2% (2010: between 2% and 7%). The results of the value in use calculations are reviewed by the Board.

The key assumptions for the value in use calculations are those regarding discount rates, revenue commencement dates, growth rates, absolute values of expected sales and expected margins and costs. Management estimate discount rates using pre-tax rates that reflect the current market assessment of the time value of money and the risks specific to the cash-generating unit. Revenue commencement dates are based on current planned launch dates. Growth rates, absolute values of expected sales and expected margins and costs are based on information received from commercial partners and market intelligence reports on expectations of future changes in the market.

Pre-tax cash flow projections are discounted to calculate value in use using a pre-tax discount rate. The pre-tax discount rate is based on a number of factors including the risk-free rate in the UK, the Group's estimated market risk premium, and a premium to reflect the inherent risk of the forecast income streams included in the Group's cash flow projections, which remain subject to contracts being agreed with prospective customers.

Further information is given in note 12 to these consolidated financial results.

2. Financial risk management

2.1 Financial risk factors

The Group's activities inevitably expose it to a variety of financial risks: market risk (including currency risk, cash flow interest rate risk and fair value interest rate risk), credit risk and liquidity risk.

It is Group policy not to enter into speculative positions using complex financial instruments. The Group's primary treasury objective is to minimise exposure to potential capital losses whilst at the same time securing favourable market rates of interest on Group cash deposits using money market deposits with banks. Cash balances used to settle the liabilities from operating activities are also maintained in current accounts which earn interest at variable rates.

(a) Market risk

Foreign exchange risk

The Group primarily enters into contracts which are to be settled in UK pounds. However, some contracts involve other major world currencies including the US Dollar and the Euro. Where large contracts of more than £50,000 total value are to be settled in foreign currencies consideration is given to converting the appropriate amounts to or from UK pounds at the outset of the contract to minimise the risk of adverse currency fluctuations.

The Group incurred minimal expenditure in foreign currencies during the year, and the prior year, and consequently there is no material exposure to foreign currency rate risk.

Cash flow and fair value interest rate risk

The Group's interest rate risk arises from medium term and short term money market deposits. Deposits which earn variable rates of interest expose the Group to cash flow interest rate risk. Deposits at fixed rates expose the Group to fair value interest rate risk.

The Group analyses its interest rate exposure on a dynamic basis throughout the year.

(b) Credit risk

Credit risk arises from cash and cash equivalents and deposits with banks and financial institutions as well as credit exposure in relation to outstanding receivables. Group policy is to place deposits with institutions with investment grade A2 or better (Moody's credit rating) and deposits are made in sterling only. The Group does not expect any losses from non-performance by these institutions. Management believes that the carrying value of outstanding receivables and deposits with banks represents the Group's maximum exposure to credit risk.

(c) Liquidity risk

Liquidity risk arises from the Group's management of working capital, it is the risk that the Group will encounter difficulty in meeting its financial obligations as they fall due. Prudent liquidity risk management implies maintaining sufficient cash and cash equivalents and management monitors rolling forecasts of the Group's liquidity on the basis of expected cash flow.

The Group had trade and other payables at the statement of financial position date of £563,190 (2010: £295,498) as disclosed in note 16.

2.2 Capital risk management

The Group considers its capital to comprise its ordinary share capital, share premium, warrant reserve, merger reserve and accumulated retained earnings as disclosed in the consolidated statement of financial position.

The Group remains funded primarily by equity capital which reflects the development status of its products. The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for equity holders of the Company and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

2.3 Fair value estimation

The Group uses amortised cost, using the effective interest rate method, to determine subsequent fair value after initial recognition, for its financial instruments.

3. Segmental reporting

The Directors have determined that only one operating segment exists under the terms of International Financial Reporting Standard 8 'Operating Segments', as the Group is organised and operates as a single business unit and all activities are based in the UK..

4. Grant income

5. Loss from operations

The total fees of the Group's auditor, BDO LLP, for services provided are analysed below:

6. Wages and salaries

The average monthly number of persons (including all Directors) employed by the Group during the year was as follows:

Their aggregate emoluments were:

7. Directors' emoluments

Emoluments disclosed above include the following amounts in respect of the highest paid Director:

During the year, three Directors (2010: three Directors) participated in defined contribution pension schemes.

Directors' emoluments include amounts attributable to benefits in kind comprising private medical insurance on which the directors are assessed for tax purposes. The amounts attributable to benefits in kind are stated at cost to the Group, which is also the tax value of the attributable benefits.

8. Finance income

9. Taxation

The tax assessed for the year is different from the standard rate of corporation tax in the UK. The differences are explained below:

At 31 March 2011 the Group UK tax losses to be carried forward are estimated to be £14,488,679 (2010: £13,398,578).

9. Taxation (continued)

Deferred tax

Deferred tax assets amounting to £4,093,379 (2010: £4,391,974) have not been recognised on the basis that their future economic benefit is not certain. Assuming a prevailing tax rate of 26% (2010: 28%) when the timing differences reverse, the unrecognised deferred tax asset comprises:

10. Loss per share

Basic and diluted loss per share amounts are calculated by dividing the loss attributable to owners of the parent by the weighted average number of ordinary shares in issue during the period.

There are 62,471,648 share options in issue (2010: 62,471,648) that are all currently anti-dilutive and have therefore been excluded from the calculations of the diluted loss per share.

Basic and diluted loss per share amounts are in respect of all activities.

11. Intangible assets

Development costs represent costs incurred in registering patents that meet the capitalisation criteria set out in IAS 38, see also note 1.

12. Goodwill and impairment

Goodwill arising on consolidation represents the excess of the cost of an acquisition over the fair value of the Group's share of the net assets of the acquired subsidiary at the date of acquisition.

Goodwill arose on 23 June 2005 when the Company acquired the entire issued share capital of Provexis Natural Products Limited (formerly Provexis Limited), a private company engaged in research and development. Provexis Natural Products Limited has been consolidated using the purchase method and its results have been incorporated in the Group results from the date of acquisition.

Goodwill arising on business combinations is not amortised but is reviewed for impairment on an annual basis or more frequently if there are indications that goodwill may be impaired.

The recoverable amount of goodwill is determined based on value in use calculations of the cash-generating units to which it has been allocated.

The key assumptions for the value in use calculations are those regarding discount rates, revenue commencement dates, growth rates, absolute values of expected sales and expected margins and costs. Management estimate discount rates using pre-tax rates that reflect the current market assessment of the time value of money and the risks specific to the cash-generating unit. Revenue commencement dates are based on current planned launch dates. Growth rates, absolute values of expected sales and expected margins and costs are based on information received from commercial partners and market intelligence reports on expectations of future changes in the market. The growth rates used are below the long-term growth rates for the Nutraceuticals industry.

The value in use calculations use pre-tax cash inflow projections for nine years using data from the Group's approved internal forecasts. The cash inflow forecasts are extrapolated beyond nine years at growth rates of 2% (2010: between 2% and 7%) for a further 6 years and thereafter at a nil growth rate in perpetuity. The results of the value in use calculations are reviewed by the Board. 

The Directors believe that it is appropriate to use internally approved forecasts for a period of 9 years as this will give a more accurate estimate of the likely growth patterns in the early stages of the product's life than the application of a single growth rate.

The value in use calculations use pre-tax cash outflows for two to four years based on approved budgets. The cash outflow forecasts are extrapolated beyond two to four years at growth rates of 2% for a further 13 or 11 years (2010: 2%) and thereafter at a nil growth rate in perpetuity. The results of value in use calculations are reviewed by the Board.

The values used in the Group's internal forecasts reflect anticipated market developments, following discussions with prospective customers and suppliers. An element of the risk inherent in the forecast income streams, which remain subject to contracts being agreed with prospective customers, has been incorporated in the Group's pre-tax cash flow projections and discount rates.

Pre-tax cash flow projections have been discounted to calculate value in use using pre-tax discount rates of 15.8% and 29.8% (2010: 23%) reflecting the stage of development of their respective cash generating units. No impairment charge was required in the current or previous year.

The pre-tax discount rate is based on a number of factors including the risk-free rate in the UK, the Group's estimated market risk premium, and a premium to reflect the inherent risk of the forecast income streams included in the Group's cash flow projections, which remain subject to contracts being agreed with prospective customers.

13. Plant and equipment

14. Trade and other receivables

The Directors consider that the carrying amount of these receivables approximates to their fair value.

All amounts shown under receivables fall due for payment within one year.

15. Cash and cash equivalents

16. Trade and other payables

The Directors consider that the carrying amount of these liabilities approximates to their fair value.

All amounts shown fall due within one year.

17. Share capital

On 31 March 2010 the Company announced that it had secured a 3 year Equity Financing Facility of up to £25m (the "EFF") with Evolution Securities Limited ("Evolution"). The EFF was arranged by Darwin Strategic Limited ("Darwin"), an appointed representative of Evolution.

On 22 June 2010 the Company announced that it had raised a net £88,426 by drawing down on the EFF, allotting 2,135,000 new ordinary shares of 0.1p each to Darwin.

On 4 October 2010 the Company announced that it had raised a further net £2.4m by drawing down on the EFF, allotting 86,300,000 new ordinary shares of 0.1p each to Darwin.

The EFF agreement, provides the Company with a facility which (subject to certain limited restrictions) can be drawn down at any time over the 3 years ending on 29 March 2013. The timing and amount of any draw down is at the discretion of Provexis. Provexis is under no obligation to make a draw down and may make as many draw downs as its wishes, up to the total value of the EFF, by way of issuing subscription notices to Evolution. Following delivery of a subscription notice, Evolution will subscribe and Provexis will allot to Evolution new ordinary shares of 0.1p each ("Ordinary Shares").

The subscription price for any Ordinary Shares to be subscribed by Evolution under a subscription notice will be at a 7.5% discount to an agreed reference price determined during 5, 10 or 15 trading days following delivery of a subscription notice (the "Pricing Period"). The length of the Pricing Period is at the discretion of Provexis and is set at each relevant subscription notice. Provexis is also obliged to specify in each subscription notice a minimum price below which Ordinary Shares will not be issued.

Warrant reserve

In consideration of Evolution agreeing to provide the EFF the Company entered into a warrant agreement dated 30 March 2010 for the grant to Evolution of warrants to subscribe for up to ten million Ordinary Shares, such warrants to be exercisable at a price of 20 pence per share and to be exercisable at any time prior to the expiry of 36 months following the date of the warrant agreement.

The warrants were measured at fair value at the date of grant using a Black-Scholes model, with the following assumptions:

Warrant reserve (continued)

An expected dividend yield of 0% was used in the above valuation.

The assumption made for the expected life of the warrants is not necessarily indicative of the exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.

The total fair value of the warrants, £115,980, has been held on the balance sheet within prepayments and in the warrants reserve within equity. The prepayment will be released against share premium as the equity financing facility is utilised. The warrants reserve will be released to share premium when the warrants are exercised. If the warrants lapse then the reserve is transferred to retained earnings.

Evolution or the Company may terminate the EFF in specified circumstances. The issue of subscription notices is subject to specified pre-conditions. The Company has provided warranties and indemnities to Evolution and affiliated persons. If the aggregate price paid for the Ordinary Shares allotted under the EFF by the second anniversary of the EFF is not equal to or more than five million pounds (subject to certain exceptions), or if the EFF is terminated by Evolution in certain circumstances, then the Company will be required to pay a fee to Evolution amounting to 1% of the value of the facility in cash or by an issue of fully paid ordinary shares at the Company's discretion.

17. Share capital (continued)

Share re-organisation

In August 2008, to facilitate a share placing, the company undertook a share re-organisation when It was agreed to sub-divide:

·; each of the 401,724,366 then issued existing ordinary shares of 1p each in the capital of the Company into one new ordinary share of 0.1p and one Deferred Share of 0.9p; and

·; each of the 148,275,634 unissued ordinary shares of 1p each into 10 new ordinary shares of 0.1p each,

The share re-organisation was approved at an EGM on 26 August 2008.

The rights attached to the new ordinary shares are substantially the same as the rights attached to the original, pre placing ordinary shares. The Deferred Shares have very limited rights which are deferred to the new ordinary shares and effectively carry no value as a result. Accordingly, the holders of the Deferred Shares are not entitled to receive notice of, attend or vote at general meetings of the Company; nor be entitled to receive any dividends or any payment on a return of capital until at least £10,000,000 has been paid on each new ordinary share. No application will be made for the Deferred Shares to be admitted to trading on AIM. No certificates for the Deferred Shares will be issued.

Full details of the share re-organisation were provided in a circular to shareholders on 1 August 2008. The circular is available to download from the Company's website www.provexis.com.

17. Share capital (continued)

During the year ended 31 March 2011 the Company issued ordinary shares of 0.1p each as follows:

During the year ended 31 March 2010 the Company issued ordinary shares of 0.1p as follows:

18. Share options

In June 2005 the Company adopted a new share option scheme for employees ("the Provexis 2005 share option scheme"). Under the scheme, options to purchase ordinary shares are granted by the Board of Directors, subject to the exercise price of the option being not less than the market value at the grant date. The options typically vest after a period of 3 years and the vesting schedule is subject to predetermined overall company selection criteria. In the event that the option holder's employment is terminated, the option may not be exercised unless the Board of Directors so permits. The options expire 10 years from the date of grant.

The Company undertook a reverse takeover of Provexis Natural Products Limited ("PNP", formerly Provexis Limited) in June 2005 through a share for share exchange. Prior to the takeover the Company and PNP had granted EMI options and unapproved options. Options granted by the Company prior to the takeover remain subject to the same terms as contained in the individual share option contracts under which they were originally granted. The PNP EMI options and unapproved options were rolled over into options over the Company's ordinary shares, and these replacement options remain subject to the same terms as contained in the individual PNP share option contracts under which they were originally granted.

On 1 September 2008 the Company announced that further to an announcement on 1 August 2008 the Company's Remuneration Committee had approved the grant of options over 62,471,648 ordinary shares of 0.1p each to certain Directors and employees of the Company. As a condition of the grant of options, certain Directors surrendered 19,089,110 existing options and an additional 3,709,384 existing options were surrendered by other existing employees.

On 15 October 2009 the Company's Remuneration Committee modified the Performance Period and Performance Target of share options over 62,471,648 ordinary shares of 0.1p each held by the Executive Directors and employees of the Company.

Following the changes agreed to the Performance Period and Performance Target, share options over 27,305,073 ordinary shares of 0.1p each held by certain Directors and employees of the Company vested on 15 October 2009. Share options over 35,166,575 ordinary shares of 0.1p each held by certain Directors and employees of the Company will vest on 1 April 2011.

18. Share options (continued)

At 31 March 2011 the number of ordinary shares subject to options granted over the 2005 and prior option schemes were:

EMI options

The exercise price of EMI options outstanding at the end of the year ranged between 0.9p and 6.28p (2010: 0.9p and 6.28p) and their weighted average contractual life was 7.3 years (2010: 8.3 years).

Of the total number of EMI options outstanding at the end of the year, 23,709,976 (2010: 23,709,976) had vested and were exercisable at the end of the year. Their weighted average exercise price was 1.3 pence (2010: 1.8 pence).

Unapproved options

The exercise price of unapproved options outstanding at the end of the year ranged between 0.9p and 6.28p (2010: 0.9p and 6.28p) and their weighted average contractual life was 6.3 years (2010: 7.3 years).

Of the total number of unapproved options outstanding at the end of the year, 3,595,097 (2010: 3,595,097) had vested and were exercisable at the end of the year. Their weighted average exercise price was 1.7 pence (2010: 1.7 pence).

18. Share options (continued)

Grant of options

The fair values of the options have been estimated at the date of grant using a Black-Scholes model, using the following assumptions:

An expected dividend yield of 0% has been used in all of the above valuations.

The expected life of the options is based on historical data and is not necessarily indicative of the exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.

The total charge for the year relating to employee share-based payment plans was £69,069 (2010: £225,909) all of which related to equity settled share-based payment transactions.

The Company carried out a share re-organisation on 28 August 2008, which is further detailed in note 17 to the consolidated financial results.

Share options which had been granted prior to 28 August 2008 over existing ordinary shares with a nominal value of 1p each in the capital of the Company became options over new ordinary shares with a nominal value of 0.1p each in the capital of the Company. The options remain subject to the same terms as contained in the individual option contracts under which they were originally granted.

Share options issued after 28 August 2008 are options over new ordinary shares with a nominal value of 0.1p each in the capital of the Company.

19. Reserves

The following describes the nature and purpose of each reserve within total equity:

20. Pension costs

The pension charge represents contributions payable by the Group to independently administered funds which during the year ended 31 March 2011 amounted to £37,370 (2010: £31,581). Pension contributions payable but not yet paid at 31 March 2011 totalled £26,051, in respect of pension contribution entitlements where employees had not yet provided details of the funds to which the contributions should be made (2010: £16,368). In addition, pension contributions payable in arrears at 31 March 2011 totalled £ Nil (2010: £1,189). All unpaid contributions are included in accrued social security costs at the balance sheet date.

21. Operating lease commitments

Future minimum rentals payable under non-cancellable operating leases are as follows:

Operating lease payments represent rentals payable by the Group for various offices. The leases have various terms, escalation clauses and renewal rights typical of lease agreements for the class of asset.

22. Related party transactions

On 12 February 2010 the Company announced that it had entered into a Letter of Intent ("LOI") for its Fruitflow® technology with DSM Nutritional Products ("DSM").

The LOI provided a framework for the parties to develop a long-term Alliance Agreement (the "Agreement"), giving DSM exclusive global rights to Fruitflow®.

On 1 June 2010 the Company announced a long-term Alliance Agreement with DSM Nutritional Products, which will see the Company collaborate with DSM to develop Fruitflow® in all major global markets. DSM will invest substantially in the manufacture, technology development, marketing and sale of Fruitflow® in the coming years. Provexis will continue to contribute scientific expertise and will collaborate in areas such as cost of goods optimisation and regulatory matters. The financial model is based upon the division of profits between the two partners on an agreed basis, linked to certain revenue targets, following the deduction of the cost of goods and a fixed level of overhead from sales. The Company is working closely with DSM in various areas related to launch planning. It is not possible to determine the financial impact of the Alliance Agreement at this time.

DSM is classified as a related party of the Group in accordance with IAS 24 as it holds shares in the Group. Further, K Rietveld is a director of the Company, and a senior employee of DSM. The directors of Provexis (the "Directors"), having consulted with Evolution Securities Limited ("Evolution Securities"), the Company's nominated adviser, consider that the terms of the letter of intent and the Alliance Agreement are fair and reasonable insofar as Provexis's shareholders are concerned. In providing advice to the Directors, Evolution Securities has taken into account the Directors' commercial assessments.

On 1 June 2011 the Group announced an agreement to commercialise DSM owned intellectual property, through the development of a new product for the promotion of healthy blood glucose levels.

Key management compensation

The Directors represent the key management personnel. Details of their compensation and share options are given in note 7 and within the Remuneration report.

23. Post balance sheet events

On 1 June 2011 the Group announced an agreement to commercialise DSM owned intellectual property, through the development of a new product for the promotion of healthy blood glucose levels.

On 17 June 2011 the Group entered into a conditional agreement to acquire 100% of the issued share capital of SiS, a company which manufactures and sells sports nutrition products for a maximum consideration of £8m, subject to completion. £7m is payable in cash of which £250,000 is to be held in escrow against claims for one year or longer if claims have been notified but not settled. The balance of the consideration is £1m in Provexis shares, with a lock-in of two years. The £7m cash consideration will be met by £4.5m from current cash reserves and £2.5m from a placing for new shares. The Company intends to undertake an Open Offer to shareholders of the Company as soon as is reasonably practicable after the completion of the Acquisition.

Completion of the acquisition is dependent on the fulfilment of certain conditions, which had not been met at the date of approval:

·; the admission by the London Stock Exchange of the consideration shares to AIM becoming effective in accordance with the AIM Rules; and

·; a placing agreement between the Company and Evolution Securities Limited concerning the placing becoming unconditional in all respects (save for the condition in the placing agreement that the agreement concerning the Acquisition becomes unconditional).

Since the acquisition agreement entered into on 17 June 2011 is conditional, and completion has therefore not yet occurred, control is not deemed to have passed to the Company as at the date of approval of the financial information and there is therefore no requirement to provide IFRS 3 disclosures in respect of a post balance sheet acquisition. However, in the interests of full disclosure, we have included those disclosures for which information is available at the date of approval.

For the financial year ended 31 December 2010, SiS had unaudited turnover of £4.6 million (2009: £4.3 million (unaudited)) and unaudited profit before tax of £0.2 million (2009: £0.4 million (unaudited)). As at 31 December 2010, SiS had unaudited net assets of £0.96 million (2009: £0.8 million (unaudited)).